Zytiga creeps up on Provenge prostate-cancer drug
7 October 2011
By Ransdell Pierson, Reuters
[..] Gulley is leading clinical trials of an
experimental vaccine to treat prostate cancer that could be taken
out of the freezer and injected into patients -- eliminating the
hassles seen with Provenge.
The National Cancer Institute developed the vaccine, called
ProstVac, and licensed it to Danish biotechnology company Bavarian
Nordic . NCI would be entitled to royalties on sales of the
vaccine, which is slated to move into late-stage trials in coming
weeks.
Gulley said ProstVac prolonged patient lives by eight months in
mid-stage trials -- roughly twice the benefit seen in separate
trials of Provenge and Zytiga. But he cautioned that ProstVac's
true potential will not be known until its far-larger planned Phase
III trials are completed.
He said the vaccine, which coaxes immune system T-cells to
attack a protein called Prostate-Specific Antigen (PSA) -- could
prove to be a bigger drug than Provenge.
"Here's why: because it is off the shelf. There are no
logistical constraints."
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
